NCT04222374

Uro-DNA Collection for Expanded Genome-Wide Association Study (GWAS) of Renal Cell Carcinoma (RCC)

Uro-DNA Collection for Expanded Genome-Wide Association Study (GWAS) of Renal Cell Carcinoma (RCC) (Uro-DNA - GWAS)

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 200 (actual)
• Sponsor: University Hospital, Bordeaux · Academic / Other
• Sex: All
• Age: 18 Years – 100 Years
• Healthy volunteers: Not accepted

Summary

In the last decade, investigators from the Department of Cancer Epidemiology and Genetics (National Cancer Institute, USA) have conducted genome-wide association (GWAS) studies of renal cell carcinoma. Dr. Mark PURDUE and Dr. Stephen CAHNOCK (Department of Epidemiology of Cancer and Genetics, NCI) propose to expand their genome-wide association study (Expanded GWAS) by genotyping approximately 10,000 additional cases of kidney cancer patients, in collaboration with US institutions, South-American and European. This study describes the participation of the French Kidney Cancer Research Network (UroCCR) in the Expanded GWAS research, under the coordination of Professor BERNHARD (Bordeaux University Hospital).

Detailed description

The aim of the Expanded GWAS study is to better understand the role of common genetic variants in susceptibility to renal cell carcinoma (RCC). The participation of the French UroCCR network consists in completing the bio-collection of the UroCCR cohort by preserving constitutional DNA and to provide DNA samples to the US NCI team. This will increase the number of samples for meta-analysis and contribute to better identify clear cell kidney cancer susceptibility loci.

Conditions

• Kidney Cancer

Interventions

Type	Name	Description
PROCEDURE	Intervention in the UroCCR sites	1. Blood sampling of a 5ml tube per patient. (for eligible patients recruited in the study, after signing the consent) 2. DNA extraction: * For the patients of Bordeaux University Hospital, 2 aliquots will be constituted: * 1 aliquot for Expanded GWAS, containing at least 2 μg of DNA, * 1 aliquot for the UroCCR biobank. * For patients from other UroCCR centers, only 1 aliquot will be constituted: * 1 aliquot for Expanded GWAS, containing at least 2 μg of DNA. 3. Transmission of the extracted DNA samples to the Biological Resource Center (CRB) of Bordeaux.
PROCEDURE	Intervention in the CRB of Bordeaux University Hospital	1. Temporary storage of DNA samples for Expanded GWAS before shipping to the NCI. Storage of samples for the DNA biobank. 2. Overall packing of GWAS samples for shipment to the NCI. 3. Shipping to the NCI: Constitutive DNA samples must be sent to the NCI by May 1, 2020 for inclusion in the Expanded GWAS study.
PROCEDURE	Intervention at the Methodology and Data Management Centre of Bordeaux University Hospital	Transfer of the data associated with the samples to the NCI.
PROCEDURE	Subsequent intervention at the NCI (for information)	1. Samples will be genotyped at the NCI Cancer Genomics Research Lab using the Illumina Global Screening Network. 2. GWAS combined meta-analysis, based, among others, on the results from the UroCCR samples.

Timeline

• Start date: 2019-12-10
• Primary completion: 2020-05-01
• Completion: 2020-05-01
• First posted: 2020-01-10
• Last updated: 2020-07-13

Locations

1 site across 1 country: France